ImmunityBio, Inc. (NASDAQ: IBRX) shares plummeted 5.09% during Tuesday's intraday trading session, following the company's release of its Full Year 2024 financial results. Despite beating earnings per share (EPS) expectations, the biotechnology firm's revenue fell short of analyst estimates, weighing on investor sentiment.
According to the report, ImmunityBio generated revenue of $14.7 million for the fiscal year 2024, up from $0.6 million in the previous year but missing analysts' forecasts by 31%. However, the company reported a narrower net loss of $413.6 million, translating to an EPS loss of $0.59, which exceeded expectations by 26%.
While ImmunityBio's revenue growth trajectory remains strong, with a projected 55% annualized increase over the next three years, investors appear to have reacted negatively to the missed revenue target. The company's shares are now down 11% from a week ago.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。